Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Arrow Financial

Community Trust Bancorp

Chevron

Enbridge

Essex Property Trust

Federal Realty Investment Trust

KFA Mount Lucas Index Strategy ETF

Altria

Philip Morris

The NY Fed estimates a 68% recession probability within the next 12 months, the highest risk in 42 years. Dividend aristocrats can provide a relatively safe investment option during a recession, with a history of raising dividends through economic downturns and much lower volatility. A diversified high-yield portfolio of dividend aristocrats can offer market-like returns with lower volatility and higher yield.

10 Dividend Aristocrats For The Ultimate 6% Yielding Retirement Portfolio

Genuine Parts

Kimberly-Clark

Coca-Cola

Walmart

With the debt ceiling issue once again kicked down the proverbial road, investors can focus on what the upcoming summer months will have to offer, and it may not be pretty.

The Narrow Rally Likely Is Almost Over: 7 ‘Strong Buy' Safe-Haven Dividend Kings to Buy Now

Amgen

Today, Coherus and Mark Cuban announced a partnership to launch an ultra-low-priced Humira biosimilar. This steep discount might have negative consequences for both AbbVie and Amgen later on this year.

Why AbbVie and Amgen Are Moving Lower Today

Caterpillar

CME Group

Canadian Pacific Kansas City Limited

Carlisle Companies

Deere & Company

Danaher

Duke Energy

Extra Space Storage

Huntington Bancshares

Home Depot

L3Harris

Lockheed Martin

Nasdaq

Northrop Grumman

Norfolk Southern

PepsiCo

Public Storage

Pioneer Natural Resources

Raytheon Technologies

Union Pacific

Vanguard Dividend Appreciation ETF

Valero Energy

Exxon Mobil

My dividend growth portfolio consists of 22 individual stocks in eight sectors, with a focus on industries with high entry barriers and dominant positions in supply chains. The portfolio has delivered solid returns, outperforming the S&P 500 by 400 basis points annually since 2013, despite recent market challenges. Going forward, I plan on adding to cyclical holdings and expanding my real estate exposure while maintaining my long-term investment strategy.

My Improved Six-Figure Market-Beating Dividend Growth Portfolio

Black Hills

Cincinnati Financial

Emerson Electric

Gorman-Rupp

Leggett & Platt

National Fuel Gas

Northwest Natural Gas

Sysco

Target

Universal Corp

V.F.

"There is only one-criterion to be included among the Dividend Kings: a publicly-traded company must increase its total fiscal-year dividend-payout for a minimum of 50 consecutive-years."--Dogs of the Dow. The 47 Dividend Kings screened as of May 26, 2023, represented eight of eleven Morningstar Sectors. Broker targeted-top-ten net-gainers ranged 16.08%-39.93% topped-by VF Corp & Gorman-Rupp. By yield, MO tops-all. Top-ten Kingly June yields from BKH, ABBV, NWN, FRT, CDUAF, LEG, UVV, MMM, VFC, & MO averaged 5.59%.

Buy 7 June Dividend Kings And Watch 3

-  At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary endpoint of systemic lupus erythematosus (SLE) Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day in patients with moderately to severely active SLE receiving standard lupus therapies1 -  Upadacitinib maintained greater improvements in SLE disease activity at week 48 as measured by the British Isles Lupus Assessment Group-Based Composite Lupus Assessment (BICLA), SRI-4, Lupus Low Disease Activity State (LLDAS) and lupus flares compared with placebo2 -  No new safety signals were observed beyond the known safety profile for upadacitinib. Types of adverse events reported with ABBV-599 high dose were similar to those reported for patients treated with upadacitinib alone2 -  Study results are being presented as an oral presentation at the European Congress of Rheumatology, EULAR 2023 NORTH CHICAGO, Ill.

Phase 2 Study of Upadacitinib (RINVOQ®) Alone or as a Combination Therapy Meets Primary and Key Secondary Endpoints in Patients with Systemic Lupus Erythematosus

Abbott Labs

Magellan Midstream Partners

Realty Income Corp

ONEOK

This article discusses three high-yielding stocks for retirees and income-oriented investors: ONEOK, AbbVie, and Realty Income. ONEOK is a cyclical income play with a 6.5% yield, AbbVie offers a high-quality healthcare yield of 4.2%, and Realty Income provides steady and reliable dividend growth with a 5.2% yield.

Buy Alert: 3 Undervalued High-Yield Gems For Your Retirement

Eli Lilly

Looking at stock returns, Eli Lilly has outperformed AbbVie and the broader indices.

Should You Pick AbbVie Stock Over LLY?

AbbVie's Humira now faces competition from biosimilars, but things look more promising in the long run. 3M's margins have been shrinking, but its biggest risk is the plethora of lawsuits relating to its earplugs.

2 Dividend Kings on Sale That Are Yielding More Than 4%

AbbVie has raised its dividend for the last 51 years. Coca-Cola has hiked its dividend for the past 61 years.

2 Top Dividend Kings to Buy for the Long Haul

NORTH CHICAGO, Ill. , May 25, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the New England Journal of Medicine (NEJM) published results from the pivotal Phase 3 clinical trials – U-EXCEL, U-EXCEED and U-ENDURE – evaluating upadacitinib (RINVOQ®) in adult patients with moderately to severely active Crohn's disease who have had an inadequate response, lost response or were intolerant to conventional therapy or a biologic agent.1-4 The publication reports the safety and efficacy results of oral upadacitinib versus placebo in two induction studies (U-EXCEL and U-EXCEED) and one maintenance study (U-ENDURE), evaluating the co-primary endpoints of clinical remission and endoscopic response.

New England Journal of Medicine Publishes Results from Phase 3 Induction and Maintenance Programs Evaluating Upadacitinib (RINVOQ®) in Crohn's Disease

-  Five-year results from SELECT-COMPARE evaluating the efficacy and safety of RINVOQ® (upadacitinib) and HUMIRA® (adalimumab), both in combination with methotrexate (MTX), are reported for adult patients with moderate to severely active rheumatoid arthritis (RA) who had an inadequate response to MTX1 -  Three-year results from SELECT-PsA 1 evaluating the efficacy and safety of RINVOQ are reported in psoriatic arthritis (PsA) patients with prior inadequate response (IR) or intolerance to one or more non-biologic disease-modifying antirheumatic drugs (DMARDs)2 -  One-year efficacy and safety data of RINVOQ are reported in SELECT-AXIS 2 for patients with active ankylosing spondylitis (AS) who had an inadequate response to biologic DMARD therapy3 NORTH CHICAGO, Ill. , May 24, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that researchers will present new, long-term data supporting the efficacy and safety profile of RINVOQ® (upadacitinib) from the SELECT-COMPARE, SELECT-PsA 1 and SELECT-AXIS 2 studies at the European Congress of Rheumatology, EULAR 2023, taking place from 31 May – 3 June in Milan.

AbbVie Presents Long-Term Data Further Supporting the Efficacy and Safety Profile of RINVOQ® (upadacitinib) Across Multiple Rheumatic Diseases at the EULAR 2023 Congress

CVS Health

Johnson & Johnson

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

Wall Street's Most Accurate Analysts Say Buy These 3 Health Care Stocks With Over 3% Dividend Yields - CVS Health (NYSE:CVS), AbbVie (NYSE:ABBV)

Apple

AGNC Investment

AGNC Investment Corp - FXDFR PRF PERPETUAL USD 25 - Ser D 1/1000th int

AGNC Investment Corp. Deposit Shs Repr 1/1000th Cum Conv Red Pfd Registered Shs Series C

Allianz SE

Antero Midstream Partners

Apple Hospitality REIT

Ares Capital

Apollo Commercial Real Estate Finance

Broadcom

Markets are racing higher as the earnings season turned out much better than expected. Sector rotation into tech stocks has led to a surge in big-tech with Nvidia clearly leading the pack.

My Dividend Stock Portfolio: New April Dividend Record - 99 Holdings With 21 Buys

News for AbbVie Stock (ABBV)